Search
Dinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalBy binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the
Simeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawnThis class of antiviral drugs were the first direct acting antivirals approved but are associated with lower cure rates than newer drugs. … Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and [DB05521] but is classified as a second generation protease inhibitor.
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized by
Rosiglitazone
go.drugbank.com/drugs/DB00412ApprovedInvestigationalIt is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). … Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ
Povidone
go.drugbank.com/drugs/DB11061ApprovedInvestigationalWithdrawnPovidone, also known as polyvinylpyrrolidone (PVP) or polyvidone, is a synthetic water-soluble polymer made from the monomer N-vinylpyrrolidone used as a binder in many pharmaceutical tablets and lubricant in eye drops. It is also used i...
Mixtures: SK Advanced Relief Eye DropsClomifene
go.drugbank.com/drugs/DB00882ApprovedInvestigationalA triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
Lutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalLutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. … emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by
LX1031
go.drugbank.com/drugs/DB05199InvestigationalLX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels. … LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system
Imiglucerase
go.drugbank.com/drugs/DB00053ApprovedInvestigationalAlglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.
Products: CEREZYME 400 U/10 ML İNFÜZYONLUK KONSANTRE ÇÖZELTİ İÇİN TOZ, CEREZYME 200 U INFUZYONLUK KONSANTRE ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADETXimelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.